166 related articles for article (PubMed ID: 37949450)
1. Discovery of
Novotná K; Tenora L; Prchalová E; Paule J; Alt J; Veeravalli V; Lam J; Wu Y; Šnajdr I; Gori S; Mettu VS; Tsukamoto T; Majer P; Slusher BS; Rais R
J Med Chem; 2023 Nov; 66(22):15493-15510. PubMed ID: 37949450
[TBL] [Abstract][Full Text] [Related]
2. Tumor-Targeted Delivery of 6-Diazo-5-oxo-l-norleucine (DON) Using Substituted Acetylated Lysine Prodrugs.
Tenora L; Alt J; Dash RP; Gadiano AJ; Novotná K; Veeravalli V; Lam J; Kirkpatrick QR; Lemberg KM; Majer P; Rais R; Slusher BS
J Med Chem; 2019 Apr; 62(7):3524-3538. PubMed ID: 30892035
[TBL] [Abstract][Full Text] [Related]
3. Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug.
Rais R; Lemberg KM; Tenora L; Arwood ML; Pal A; Alt J; Wu Y; Lam J; Aguilar JMH; Zhao L; Peters DE; Tallon C; Pandey R; Thomas AG; Dash RP; Seiwert T; Majer P; Leone RD; Powell JD; Slusher BS
Sci Adv; 2022 Nov; 8(46):eabq5925. PubMed ID: 36383674
[TBL] [Abstract][Full Text] [Related]
4. Model studies towards prodrugs of the glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON) containing a diazo precursor.
Gao RD; Hin N; Prchalová E; Pal A; Lam J; Rais R; Slusher BS; Tsukamoto T
Bioorg Med Chem Lett; 2021 Oct; 50():128321. PubMed ID: 34400301
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 6-Diazo-5-oxo-l-norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma.
Rais R; Jančařík A; Tenora L; Nedelcovych M; Alt J; Englert J; Rojas C; Le A; Elgogary A; Tan J; Monincová L; Pate K; Adams R; Ferraris D; Powell J; Majer P; Slusher BS
J Med Chem; 2016 Sep; 59(18):8621-33. PubMed ID: 27560860
[TBL] [Abstract][Full Text] [Related]
6. We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of
Lemberg KM; Vornov JJ; Rais R; Slusher BS
Mol Cancer Ther; 2018 Sep; 17(9):1824-1832. PubMed ID: 30181331
[TBL] [Abstract][Full Text] [Related]
7. N-(Pivaloyloxy)alkoxy-carbonyl Prodrugs of the Glutamine Antagonist 6-Diazo-5-oxo-l-norleucine (DON) as a Potential Treatment for HIV Associated Neurocognitive Disorders.
Nedelcovych MT; Tenora L; Kim BH; Kelschenbach J; Chao W; Hadas E; Jančařík A; Prchalová E; Zimmermann SC; Dash RP; Gadiano AJ; Garrett C; Furtmüller G; Oh B; Brandacher G; Alt J; Majer P; Volsky DJ; Rais R; Slusher BS
J Med Chem; 2017 Aug; 60(16):7186-7198. PubMed ID: 28759224
[TBL] [Abstract][Full Text] [Related]
8. Novel Glutamine Antagonist JHU395 Suppresses MYC-Driven Medulloblastoma Growth and Induces Apoptosis.
Pham K; Maxwell MJ; Sweeney H; Alt J; Rais R; Eberhart CG; Slusher BS; Raabe EH
J Neuropathol Exp Neurol; 2021 Mar; 80(4):336-344. PubMed ID: 33712838
[TBL] [Abstract][Full Text] [Related]
9. Sirpiglenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems.
Yokoyama Y; Estok TM; Wild R
Mol Cancer Ther; 2022 Oct; 21(10):1561-1572. PubMed ID: 35930753
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and phase I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children.
Sullivan MP; Nelson JA; Feldman S; Van Nguyen B
Cancer Chemother Pharmacol; 1988; 21(1):78-84. PubMed ID: 3342470
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-activated glutamine antagonist prodrug combined with combretastatin A4 nanoparticles for tumor-selective metabolic blockade.
Zheng M; Xu H; Huang Y; Sun J; Zhang H; Lv Z; Liu Z; Tang Z; Chen X
J Control Release; 2024 Jan; 365():480-490. PubMed ID: 38040341
[TBL] [Abstract][Full Text] [Related]
12. DON/DRP-104 as potent serine protease inhibitors implicated in SARS-CoV-2 infection: Comparative binding modes with human TMPRSS2 and novel therapeutic approach.
Oduro-Kwateng E; Soliman ME
J Cell Biochem; 2024 Jan; ():. PubMed ID: 38284235
[TBL] [Abstract][Full Text] [Related]
13. A redox-responsive prodrug for tumor-targeted glutamine restriction.
Prange CJ; Sayed NYB; Feng B; Goepfert C; Trujillo DO; Hu X; Tang L
J Control Release; 2024 Apr; 368():251-264. PubMed ID: 38403173
[TBL] [Abstract][Full Text] [Related]
14. Modulating lipophilicity of rohitukine via prodrug approach: Preparation, characterization, and in vitro enzymatic hydrolysis in biorelevant media.
Kumar V; Bharate SS; Vishwakarma RA
Eur J Pharm Sci; 2016 Sep; 92():203-11. PubMed ID: 27422078
[TBL] [Abstract][Full Text] [Related]
15. Bioanalysis of 6-diazo-5-oxo-l-norleucine in plasma and brain by ultra-performance liquid chromatography mass spectrometry.
Alt J; Potter MC; Rojas C; Slusher BS
Anal Biochem; 2015 Apr; 474():28-34. PubMed ID: 25584882
[TBL] [Abstract][Full Text] [Related]
16. DON of Hope: Starving Pancreatic Cancer by Glutamine Antagonism.
Pillai R; Papagiannakopoulous T
Cancer Res; 2024 Feb; 84(3):349-350. PubMed ID: 38117482
[TBL] [Abstract][Full Text] [Related]
17. Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy.
Cervantes-Madrid D; Romero Y; Dueñas-González A
Biomed Res Int; 2015; 2015():690492. PubMed ID: 26425550
[TBL] [Abstract][Full Text] [Related]
18. Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine.
Wang SZ; Poore B; Alt J; Price A; Allen SJ; Hanaford AR; Kaur H; Orr BA; Slusher BS; Eberhart CG; Raabe EH; Rubens JA
Clin Cancer Res; 2019 Oct; 25(19):5925-5936. PubMed ID: 31300448
[TBL] [Abstract][Full Text] [Related]
19. Glutamine Antagonist JHU083 Normalizes Aberrant Glutamate Production and Cognitive Deficits in the EcoHIV Murine Model of HIV-Associated Neurocognitive Disorders.
Nedelcovych MT; Kim BH; Zhu X; Lovell LE; Manning AA; Kelschenbach J; Hadas E; Chao W; Prchalová E; Dash RP; Wu Y; Alt J; Thomas AG; Rais R; Kamiya A; Volsky DJ; Slusher BS
J Neuroimmune Pharmacol; 2019 Sep; 14(3):391-400. PubMed ID: 31209775
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of 6-diazo-5-oxo-L-norleucine and N-[N-gamma-glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice.
Ovejera AA; Houchens DP; Catane R; Sheridan MA; Muggia FM
Cancer Res; 1979 Aug; 39(8):3220-4. PubMed ID: 572261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
